New Risk Factors for Atherosclerosis and Patient Risk Assessment

Advances in our understanding of the ways in which the traditional cardiovascular risk factors, including standard lipid (eg, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol) and nonlipid (eg, hypertension) risk factors, interact to initiate atherosclerosis and promote the development of cardiovascular disease have enhanced our ability to assess risk in the individual patient. In addition, the ongoing identification and understanding of so-called novel risk factors may further improve our ability to predict future risk when these are included along with the classic risk factors in assessing the global risk profile. This review briefly summarizes the evidence that some newer risk factors, including impaired fasting glucose, triglycerides and triglyceride-rich lipoprotein remnants, lipoprotein(a), homocysteine, and high-sensitivity C-reactive protein, contribute to an increased risk of coronary and cardiovascular diseases.

[1]  A. Hofman,et al.  Inflammatory Mediators and Cell Adhesion Molecules as Indicators of Severity of Atherosclerosis: The Rotterdam Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[2]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[3]  A. Folsom,et al.  Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. , 1998, Circulation.

[4]  P. Elwood,et al.  Do Total and High Density Lipoprotein Cholesterol and Triglycerides Act Independently in the Prediction of Ischemic Heart Disease?: Ten-Year Follow-Up of Caerphilly and Speedwell Cohorts , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[5]  D. Levy,et al.  Association of C-Reactive Protein With Carotid Atherosclerosis in Men and Women: The Framingham Heart Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[6]  R. D'Agostino,et al.  Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. , 1999, Archives of internal medicine.

[7]  R. Holman,et al.  Underestimation of the Importance of Homocysteine as a Risk Factor for Cardiovascular Disease in Epidemiological Studies , 2001, Journal of cardiovascular risk.

[8]  M. Rutter,et al.  Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes. , 2002, Journal of the American College of Cardiology.

[9]  S. Ebrahim,et al.  Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men , 1995, The Lancet.

[10]  S. Vollset,et al.  Plasma total homocysteine and hospitalizations for cardiovascular disease: the Hordaland Homocysteine Study. , 2002, Archives of internal medicine.

[11]  P. Galan,et al.  Homocysteine, cardiovascular disease risk factors, and habitual diet in the French Supplementation with Antioxidant Vitamins and Minerals Study. , 2002, The American journal of clinical nutrition.

[12]  D. Levy,et al.  C-Reactive Protein Is Associated With Subclinical Epicardial Coronary Calcification in Men and Women: The Framingham Heart Study , 2002, Circulation.

[13]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[14]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[15]  P. Wilson,et al.  Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. , 2002, Diabetes care.

[16]  A. Evans,et al.  Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study. , 2003, Atherosclerosis.

[17]  R. Knopp,et al.  Risk factors for coronary artery disease in women. , 2002, The American journal of cardiology.

[18]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[19]  N. Sattar,et al.  Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study (WOSCOPS) , 2001, Circulation.

[20]  A. Evans,et al.  Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. , 2002, Atherosclerosis.

[21]  J. Haddow,et al.  Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. , 1998, Clinical chemistry.

[22]  W. Kannel,et al.  Diabetes and cardiovascular disease. The Framingham study. , 1979, JAMA.

[23]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[24]  W. Castelli.  Epidemiology of triglycerides: a view from Framingham. , 1992, The American journal of cardiology.

[25]  D. Levy,et al.  Coronary artery calcification in type 2 diabetes and insulin resistance: the framingham offspring study. , 2002, Diabetes care.

[26]  F. Cambien,et al.  Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease , 2003, Circulation.

[27]  P. Giral,et al.  Elevated C-Reactive Protein Constitutes an Independent Predictor of Advanced Carotid Plaques in Dyslipidemic Subjects , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[28]  J. Hokanson,et al.  Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies , 1996, Journal of cardiovascular risk.

[29]  D. Arveiler,et al.  Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur 'Infarctus du Myocarde. , 1996, Journal of lipid research.

[30]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .

[31]  R. Virmani,et al.  Elevated C-Reactive Protein Values and Atherosclerosis in Sudden Coronary Death: Association With Different Pathologies , 2002, Circulation.

[32]  A. von Eckardstein,et al.  Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. , 1996, The American journal of cardiology.

[33]  S. Azen,et al.  Triglyceride‐ and Cholesterol‐Rich Lipoproteins Have a Differential Effect on Mild/Moderate and Severe Lesion Progression as Assessed by Quantitative Coronary Angiography in a Controlled Trial of Lovastatin , 1994, Circulation.

[34]  J. Ambrose,et al.  The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study. , 2002, Journal of the American College of Cardiology.

[35]  G. Assmann,et al.  Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study , 2002, Circulation.

[36]  K. Shimada,et al.  Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. , 2003, The American journal of cardiology.

[37]  L. Csiba,et al.  Early-Onset Carotid Atherosclerosis Is Associated With Increased Intima-Media Thickness and Elevated Serum Levels of Inflammatory Markers , 2003, Stroke.

[38]  M. Pfeffer,et al.  VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial , 2000, Circulation.

[39]  C. Heeschen,et al.  Serum Level of the Antiinflammatory Cytokine Interleukin-10 Is an Important Prognostic Determinant in Patients With Acute Coronary Syndromes , 2003, Circulation.

[40]  K. Bønaa,et al.  Serum total homocysteine and coronary heart disease. , 1995, International journal of epidemiology.

[41]  A. Hoes,et al.  [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.